An educational overview of the regulatory framework governing therapeutic peptides in Australia, how the prescription pathway works, and what to look for in a legitimate service.
Important: This page is general educational information only and does not constitute medical advice. Many therapeutic peptides are prescription-only medicines in Australia. Always consult a qualified, AHPRA-registered medical practitioner before making any decisions about your health.
Many therapeutic peptides in Australia are classified as Schedule 4 prescription-only medicines. This means accessing them legally requires a valid prescription from an AHPRA-registered medical practitioner. This page explains how the prescription framework works, what a proper assessment process should involve, and what distinguishes a legitimate service from one that is operating outside the regulatory framework.
Most therapeutic peptides in Australia are classified as Schedule 4 substances under the Poisons Standard, placing them in the same category as antibiotics, blood pressure medications, and most other medicines that require a doctor's oversight before being dispensed.
Being Schedule 4 means three things. First, only an AHPRA-registered medical practitioner can legally prescribe them. Second, they can only be dispensed by a licensed pharmacy with a valid prescription. Third, possessing them without a valid prescription is illegal in most Australian states and territories.
The legal pathway mirrors the process for any other prescription medicine. A qualified doctor conducts a clinical assessment, determines whether a prescription is appropriate for that individual, and a licensed pharmacy dispenses it against that prescription.
Note on unapproved peptides: The TGA has specifically identified a number of peptide compounds as unapproved therapeutic goods that have not been evaluated for safety, quality or effectiveness. This includes compounds such as BPC-157 and CJC-1295. For these compounds, the regulatory position is that they are not approved for use in Australia regardless of how they are accessed. The TGA's current guidance on unapproved peptide products is available at www.tga.gov.au.
The prescription pathway for therapeutic peptides follows the same structure as any other prescription medicine in Australia. The steps below describe how a legitimate pathway is structured.
A legitimate pathway begins with a clinical assessment that captures the individual's medical history, current medications, existing health conditions, and relevant circumstances. This gives the prescribing doctor the information needed to make a proper clinical judgment about whether a prescription is appropriate.
An AHPRA-registered prescribing doctor reviews the assessment. They consider the individual's health history, current medications, any contraindications, and whether the compounds being considered are clinically appropriate for that person's situation. This should be a genuine clinical review, not an automated approval process.
If the doctor determines a prescription is clinically appropriate, it is issued for the specific compound at the specific dose considered appropriate for that individual. The prescription is the legal instrument that allows a licensed pharmacy to dispense the medicine.
The prescription is sent to a licensed Australian compounding pharmacy, which prepares the medicine to the prescribed specification under pharmaceutical quality standards and dispenses it against the valid prescription.
For compounds that interact with specific biological pathways, ongoing monitoring is part of responsible clinical practice. This may include blood testing before continuation protocols are approved. Ongoing oversight is what distinguishes medically supervised use from self-directed use.
As interest in therapeutic peptides has grown in Australia, so has the number of services offering access, not all of which are operating within the proper regulatory framework. The following are markers of a legitimate service.
Any AHPRA-registered medical practitioner can prescribe Schedule 4 medicines, which includes most therapeutic peptides. In practice, GPs vary significantly in their familiarity with peptide therapy. Some may not feel comfortable prescribing compounds they have limited experience with. Telehealth services that specialise in this area work with doctors who have relevant experience, which can be a more practical pathway than approaching a general practice that may not have the relevant expertise.
It is also worth noting that a GP cannot prescribe compounds that the TGA has identified as unapproved any more than a telehealth service can. The TGA's position on specific compounds applies to all prescribers equally.
The following official sources provide authoritative information on prescription medicines, unapproved therapeutic goods, and the regulatory framework in Australia:
This article is general educational information only. Nothing on this page constitutes medical advice or a recommendation to seek, obtain or use any therapeutic peptide. Always consult a qualified, AHPRA-registered medical practitioner before making decisions about your health. For the TGA's current guidance on therapeutic goods regulation and unapproved products, visit www.tga.gov.au.